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eMethods: 
There were 5.6% of the daily serum creatinine or urine output values missing to calculate the daily 
Acute Kidney Injury (AKI) scores.
1
 Last observation carried forward was used to impute missing 
serum creatinine values, as it was judged reasonable to assume that data were not collected because no 
change was expected by the clinician and 83% of missing values were for a single day only. This 
process resulted in a complete set of AKI scores for each patient while in ICU. If the patient’s “normal” 
baseline creatinine value required to calculate AKI scores were unknown (57 patients), then these were 
estimated using the lowest creatinine value of the measurement at randomization, the measurement for 
APACHE II score calculation (within the 24 hours prior to randomization) and, provided the patient 
did not have chronic renal failure, the calculated value from the Modification of Diet in Renal Disease 
equation as proposed by the Acute Dialysis Quality Initiative.
2
  Urine output was missing for <0.5% of 
scores. The overall AKI score was calculated using serum creatinine only where urine output values 
were missing. For the urine output-only AKI score, last observation carried forward was used to impute 
missing urine scores. 
There were 6.3% of daily variables missing to calculate daily SOFA scores.  Last observation carried 
forward was also used to impute missing SOFA scores.  Where scores were missing for 3 or more days 
in a row, a sensitivity analysis was carried out assigning the highest possible score on missing days to 
the vasopressin patients and the lowest possible score to the norepinephrine patients and vice versa. 
These results were similar with no difference to the conclusions drawn (data not shown). This was 
repeated for the hydrocortisone and placebo groups, again with no difference to the conclusions (data 
not shown). 
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eFigure 1. Cardiovascular variables by study drug 2 
a) Mean arterial pressure over the first seven days by study drug 2,
intention to treat analysis 
b) Maximum total norepinephrine dose over the first seven days for all
patients given study drug 2, “per protocol” analysis 
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c) Maximum total norepinephrine dose over the first seven days for
those vasopressin-group patients given study drug 2, “per protocol” 
analysis 
d) Maximum total norepinephrine dose over the first seven days for
those norepinephrine-group patients given study drug 2, “per protocol” 
analysis 
Blue circles represent the median for hydrocortisone patients, yellow circles for placebo patients. The vertical lines 
represent the interquartile range. Note that day 1 runs from the time of randomization to the end of the “ICU calendar 
day” so is therefore less than 24 hours and varies between patients.
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eFigure 2. Maximum vasopressin dose over the first seven days for 
those patients given study drug 2, “per protocol” analysis 
Blue line represents the mean for hydrocortisone patients, yellow line for placebo patients and vertical lines are 95% 
confidence intervals. Note that day 1 runs from the time of randomization to the end of the “ICU calendar day” so is 
therefore less than 24 hours and varies between patients. 
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eFigure 3. Kidney variables by study drug 2 
a) Serum creatinine over the first seven days
b) Urine output over the first seven days
Blue circles represent the median for hydrocortisone patients, yellow circles for placebo patients, “intention to treat” 
analysis. The vertical lines represent the interquartile range. Day 0 = baseline. Note that day 1 runs from the time of 
randomization to the end of the “ICU calendar day” so it is therefore less than 24 hours and varies between patients. 
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eFigure 4. Kaplan-Meier Survival Curves 
 
a) Vasopressin vs Norepinephrine 
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b) Hydrocortisone vs Placebo 
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eTable 1. Numbers of missing baseline characteristics 
 Vasopressin + 
hydrocortisone 
N=101 
Vasopressin 
+ placebo 
N=104 
Norepinephrine + 
hydrocortisone 
N=101 
Norepinephrine 
+ placebo 
N=103 
Total trial 
population 
N=409 
Age 0 0 0 0 0 
Male sex 0 0 0 0 0 
Weight  0 0 1 0 1 
Body Mass Index  7 3 5 4 19 
Caucasian ethnicity 0 0 0 0 0 
Recent surgical history 0 0 0 0 0 
APACHE II score 0 0 0 1 1 
Pre-existing conditions 0 0 0 0 0 
Organ failure      
  Respiratory 2 2 1 2 7 
  Renal 0 1 0 0 1 
  Liver 5 9 5 11 30 
  Haematological 0 4 3 4 11 
  Neurological
 
 8 5 6 5 24 
Physiological variables      
  Mean Arterial Pressure  0 0 2 1 3 
  Heart Rate  0 0 0 1 1 
  Central venous pressure  39 48 40 48 175 
  Lactate  4 1 3 1 9 
  PaO2/FiO2  9 5 5 2 21 
  Creatinine  0 2 0 0 2 
  Bilirubin  5 9 5 11 30 
  Platelets  0 4 3 4 11 
  GCS
 
 8 5 6 5 24 
Mechanical ventilation 0 0 0 0 0 
Renal Replacement therapy 0 0 0 0 0 
Volume of IV fluid in previous 4 hours  2 0 2 0 4 
Patients receiving other vasopressor at 
randomization 
0 0 0 0 0 
Time from onset of shock to receiving first 
study drug 
0 0 0 0 0 
Norepinephrine dose at randomization  0 0 0 0 0 
Source of infection 3 2 3 1 9 
APACHE – Acute Physiology and Chronic Health Evaluation, GCS- Glasgow Coma Score 
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eTable 2. Primary analysis of renal failure days using serum creatinine only criteria, and urine output only criteria 
 Vasopressin Norepinephrine Vasopressin vs 
Norepinephrine, 
Absolute 
difference 
(95% CI) 
 Hydrocortisone Placebo Total Hydrocortisone Placebo Total 
Serum creatinine criteria 
only (N) 
100 104 204 101 103 204  
28-day survivors who never 
developed renal failure, 
N/Total (%)
a
 
53/81 
(65.4) 
58/84 
(69.0) 
111/165 
(67.3) 
55/77 
(71.4) 
56/80 
(70.0) 
111/157 
(70.7) 
 
-3.4 (-13.5, 6.7) 
Renal failure free days in 
other patients
b
, days, 
median (IQR) 
7 (1-24) 12 (1-22) 9 (1-23) 12 (1-25) 14 (4-23) 12 (2-24) -2 (-10, 6) 
 
Urine output criteria only 
(N)  
99
c
 104 203 101 103 204  
28-day survivors who never 
developed renal failure, 
N/Total (%)
a
 
48/80 
(60.0) 
50/84 
(59.5) 
98/164 
(59.8) 
52/77 
(67.5) 
49/80 
(61.3) 
101/157 
(64.3) 
 
-4.6 (-15.2, 6.0) 
Renal failure free days in 
other patients
b
, days, 
median (IQR) 
7 (1,24) 14 (1,27) 10 (1,25) 15 (1,25) 15 (1,27) 15 (1,27) -5 (-11, 5) 
 
The serum creatinine only and urine output only criteria are defined by the Acute Kidney Injury Network (AKIN) group stage 3 definition
1 
a
 28 day survivors as a proportion of patients with no renal failure at baseline (one subject with no baseline renal failure data was excluded) 
b
 Other patients = those who died and / or had renal failure at any time.  
c 
Excludes one subject where renal free failure days could not be calculated due to missing urine data 
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eTable 3. Primary analysis of renal failure days and mortality analyses on an “as-treated” analysis and “per protocol 
analysis” 
 Vasopressin Norepinephrine Vasopressin vs 
Norepinephrine, 
Absolute 
difference 
(95% CI) 
 Hydrocortisone Placebo Total Hydrocortisone Placebo Total 
As treated analysis N=84 N=122 N=206 N=73 N=129 N=202  
28-day survivors who never 
developed renal failure, 
N/Total (%)
a
 
36/66 
(54.5) 
58/100 
(58.0) 
94/166 
(56.6) 
26/55 
(47.3) 
67/101 
(66.3) 
93/156 
(59.6) 
-3.0 (-13.8,7.8) 
Renal failure free days in 
other patients
b
, days, 
median (IQR) 
4 (0-21) 13 (1-25) 8 (1-24) 13 (0-25) 14 (1-25) 14 (1-25) -6 (-11, 4) 
28-day mortality, N/Total 
(%) 
31/84 
(36.9) 
33/122 
(27.0) 
64/206 
(31.1) 
26/73 
(35.6) 
29/129 
(22.5) 
55/202 
(27.2) 
3.8 (-5.0, 12.7) 
ICU mortality, N/Total (%) 30/84 
(35.7) 
29/122 
(23.8) 
59/206 
(28.6) 
22/73 
(30.1) 
28/129 
(21.7) 
50/202 
(24.8) 
3.9 (-4.7, 12.5) 
Hospital mortality, N/Total 
(%) 
33/84 
(39.3) 
36/122 
(29.5) 
69/206 
(33.5) 
26/73 
(35.6) 
33/129 
(25.6) 
59/202 
(29.2) 
4.3 (-4.7, 13.3) 
Per protocol analysis N=79 N=87 N=166 N=67 N=61 N=128  
28-day survivors who never 
developed renal failure, 
N/Total (%)
a
 
35/62 (56.5) 36/69 (52.2) 71/131(54.2) 24/49 (49) 24/47 (51.1) 48/96 (50.0) 4.2 (-8.9, 17.3) 
Renal failure free days in 
other patients
b
, days, 
median (IQR) 
5 (0-21) 12 (1-25) 9 (0-24) 13 (0-25) 14 (1-22) 14 (0-24) -5 (-11,6) 
28-day mortality, N/Total 
(%) 
28/79 (35.4) 27/87 (31.0) 55/166 (33.1) 24/67 (35.8) 20/61 (32.8) 44/128 (34.4) -1.2 (-12.1, 9.7) 
ICU mortality, N/Total (%) 27/79 (34.2) 24/87 (27.6) 51/166 (30.7) 20/67 (29.9) 20/61 (32.8) 40/128 (31.3) -0.5 (-11.2, 10.1) 
Hospital mortality, N/Total 
(%) 
30/79 (38.0) 30/87 (34.5) 60/166 (36.1) 24/67 (35.8) 21/61 (34.4) 45/128 (35.2)  1.0 (-10.0, 12.0) 
a
 28 day survivors as a proportion of patients with no renal failure at baseline (one subject with no baseline renal failure data was excluded 
b
 Other patients = those who died and / or had renal failure at any time.  
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eTable 2. Mean intravenous fluid volume administered over the first 7 
days, a) vasopressin vs norepinephrine and b) hydrocortisone vs 
placebo.  
a) 
 Vasopressin Norepinephrine 
Difference
a
 
(mls) 
95% CI  N
b
 Mean ± SD 
(mls) 
N
b
 Mean ± SD 
(mls) 
Day 1
c 
205 2889 ± 3813 204 2805 ± 2455 84 (-539,708) 
Day 2 189 3180 ± 2204 198 2934 ± 2182 246 (-192,685) 
Day 3 180 2257 ± 1811 182 2087 ± 1733 170 (-196,537) 
Day 4 158 1817 ±1620 157 1743 ±1412  74 (-263,411) 
Day 5 144 1746 ±1736 133 1657 ±1331 89 (-276,453) 
Day 6 130 1774 ± 1449 113 1501 ± 1316 273 (-77,622) 
Day 7 114 1569 ± 1150 100 1482 ± 1363 87 (-256,429) 
a 
Mean difference Vasopressin – Norepinephrine; figures may not add due to rounding 
b
 Number of subjects included in calculation of the mean 
c 
Day 1 runs from the time of randomization to the end of the “ICU calendar day” so it is therefore less than 24 hours 
and varies between patients. 
 
 
 
b)  
 Hydrocortisone Placebo 
Difference
a
 
(mls) 
95% CI  N
b
 Mean ± SD 
(mls) 
N
b
 Mean ± SD 
(mls) 
Day 1
c 
202 3021 ± 4015 207 2678 ± 2135 343 (-284,971) 
Day 2 189 3061 ± 2075 198 3047 ± 2306 14 (-425,451) 
Day 3 174 2292 ± 1970 188 2060 ± 1564 232 (-138,601) 
Day 4 153 1812 ± 1692 162 1750 ± 1337 62 (-277,402) 
Day 5 131 1798 ± 1791 146 1618 ± 1302 180 (-194,554) 
Day 6 115 1757 ± 1588 128 1548 ± 1188 209 (-148,567) 
Day 7 101 1659 ± 1349 113 1411 ± 1151 248 (-92,588) 
a
 Mean difference Hydrocortisone – Placebo; figures may not add due to rounding 
b
 Number of subjects included in calculation of the mean 
c 
Day 1 runs from the time of randomization to the end of the “ICU calendar day” so it is therefore less than 24 hours 
and varies between patients. 
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eTable 3. Mean total fluid balance over the first 7 days, a) vasopressin vs 
norepinephrine and b) hydrocortisone vs placebo.  
a) 
 Vasopressin Norepinephrine 
Difference
a
 
(mls) 
95% CI  N
b
 Mean ± SD 
(mls) 
N
b
 Mean ± SD 
(mls) 
Day 1
c 
204 2071 ± 2064 204 1885 ± 2318 186 (-242,612) 
Day 2 189 1949 ± 2256 198 1626 ± 2347 323 (-137,783) 
Day 3 177 698 ± 1974 182 554 ± 1839 144 (-252,540) 
Day 4 158 137 ± 1559 157 52 ± 1827 85 (-292,462) 
Day 5 144 -237 ± 1708 133 19 ± 1831 -256 (-676,164) 
Day 6 129 -119 ± 1718 113 -84 ± 1642 -35 (-461,391) 
Day 7 115 -16 ± 1339 99 142 ± 1302 -158 (-515,198) 
a
 Mean difference Vasopressin – Norepinephrine; figures may not add due to rounding 
b
 Number of subjects included in calculation of the mean 
c 
Day 1 runs from the time of randomization to the end of the “ICU calendar day” so it is therefore less than 24 hours 
and varies between patients. 
 
 
b) 
 Hydrocortisone Placebo 
Difference
a
 
(mls) 
95% CI  N
b
 Mean ± SD 
(mls) 
N
b
 Mean ± SD 
(mls) 
Day 1
c 
201 2001 ± 2243 207 1955 ± 2151 46 (-382,474) 
Day 2 189 1774 ± 2012 198 1794 ± 2560 -20 (-479,439) 
Day 3 173 711 ± 2099 186 545 ± 1708 166 (-234,564) 
Day 4 153 221 ± 1608 162 -25 ± 1772 246 (-129,620) 
Day 5 131 -105 ± 1912 146 -122 ± 1637 17 (-407,441) 
Day 6 114 20 ± 1838 128 -211 ± 1524 231 (-200,661) 
Day 7 102 111 ± 1294 112 7 ± 1349 104 (-252,460) 
a
 Mean difference Hydrocortisone – Placebo; figures may not add due to rounding 
b
 Number of subjects included in calculation of the mean 
c 
Day 1 runs from the time of randomization to the end of the “ICU calendar day” so it is therefore less than 24 hours 
and varies between patients. 
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eTable 4. Mean serum lactate over the first 7 days, a) vasopressin vs 
norepinephrine and b) hydrocortisone vs placebo  
a)  
 Vasopressin Norepinephrine 
Difference
a 
(mmol/L) 
95% CI  
N
b
 
Mean ± SD 
(mmol/L) 
N
b
 
Mean ± SD 
(mmol/L) 
Day 1 198 3.8 ± 3.5 194 3.6 ± 3.3 0.3 (-0.4,1.0) 
Day 2 179 3.2 ± 2.8 190 3.2 ± 3.2 0.1 (-0.6,0.8) 
Day 3 171 2.5 ± 2.8 171 2.6 ± 3.3 -0.1 (-0.8,0.6) 
Day 4 144 2.5 ± 2.8 139 2.4 ± 3.1 -0.3 (-0.9,0.3) 
Day 5 127 1.9 ± 1.5 120 1.9 ± 2.2 0.1 (-0.5,0.6) 
Day 6 109 1.9 ± 1.3 98 1.9 ± 2.2 0.0 (-0.6,0.5) 
Day 7 101 1.7 ± 0.8 90 1.7 ± 1.2 0.1 (-0.4,0.6) 
a
 Mean difference Vasopressin – Norepinephrine; figures may not add due to rounding 
b
 Number of subjects included in calculation of the mean 
 
  
b) 
 Hydrocortisone Placebo 
Difference
a 
(mmol/L) 
95% CI  
N
b
 
Mean ± SD 
(mmol/L) 
N
b
 
Mean ± SD 
(mmol/L) 
Day 1 196 3.8 ± 3.5 196 3.7 ± 3.4 0.1 (-0.5,0.8) 
Day 2 179 3.2 ± 2.8 190 3.3 ± 3.8 -0.1 (-0.9,0.5) 
Day 3 164 2.5 ± 2.8 178 2.6 ± 3.4 -0.1 (-0.8,0.5) 
Day 4 136 2.5 ± 2.8 147 2.0 ± 2.3 0.5 (-0.2,1.0) 
Day 5 116 1.9 ± 1.5 131 2.0 ± 2.5 -0.1 (-0.6,0.4) 
Day 6 99 1.9 ± 1.3 108 1.9 ± 2.4 0.0 (-0.6,0.5) 
Day 7 93 1.7 ± 0.8 98 1.9 ± 2.4 -0.2 (-0.7,0.3) 
a
 Mean difference Hydrocortisone – Placebo; figures may not add due to rounding 
b
 Number of subjects included in calculation of the mean 
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eTable 7. Mean highest heart rate over the first 7 days, a) vasopressin vs 
norepinephrine and b) hydrocortisone vs placebo 
 
a) 
 Vasopressin Norepinephrine 
Difference
a 
(beats / 
minute) 
95% CI 
 N
b
 Mean ± SD 
(beats / 
minute) 
N
b
 
Mean ± SD 
(beats / 
minute) 
Day 1 205 106 ± 23 204 108 ± 22 -2 (-6,3) 
Day 2 189 103 ± 24 198 109 ± 20 -6 (-10,-1) 
Day 3 178 106 ± 27 182 107 ± 22 -1 (-6,4) 
Day 4 158 105 ± 24 156 106 ± 21 -1 (-6,4) 
Day 5 144 107 ± 25 133 108 ± 23 -1 (-7,4) 
Day 6 131 105 ± 22 114 104 ± 19 1 (-4,6) 
Day 7 115 104 ± 22 100 102 ± 19 2 (-3,8) 
a
 Mean difference Vasopressin – Norepinephrine; figures may not add due to rounding 
b
 Number of subjects included in calculation of the mean 
 
 
b)  
 Hydrocortisone Placebo 
Difference
a 
(beats / 
minute) 
95% CI 
 
N
b
 
Mean ± SD 
(beats / 
minute) 
N
b
 
Mean ± SD 
(beats / 
minute) 
Day 1 202 108 ± 23 207 106 ± 22 2 (-2,7) 
Day 2 189 105 ± 22 198 107 ± 22 -2 (-6,2) 
Day 3 172 105 ± 25 188 107 ± 23 -2 (-7,3) 
Day 4 152 103 ± 22 162 107 ± 23 -4 (-9,1) 
Day 5 131 105 ± 22 146 110 ± 26 -5 (-10,2) 
Day 6 116 106 ± 22 129 102 ± 19 4 (-1,9) 
Day 7 102 104 ± 23 113 103 ± 19 1 (-4,7) 
a
 Mean difference Hydrocortisone – Placebo; figures may not add due to rounding 
b
 Number of subjects included in calculation of the mean 
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eTable 6. Mean serum creatinine over the first 7 days, a) vasopressin vs 
norepinephrine and b) hydrocortisone vs placebo  
a) 
 Vasopressin Norepinephrine 
Difference
a 
(mg/dl)
 95% CI  
N
b
 
Mean ± SD 
(mg/dl) 
N
b
 
Mean ± SD 
(mg/dl) 
Day 1 202 1.74 ± 1.16 204 1.96 ± 1.71 -0.22  (-0.51,0.06)   
Day 2 186 1.55 ± 1.06 197 1.74 ± 1.31 -0.19  (-0.43,0.04)   
Day 3 175 1.33 ± 0.91 175 1.56 ± 1.16 -0.23  (-0.45,-0.01)   
Day 4 153 1.20 ± 0.91 151 1.45 ± 1.12 -0.25  (-0.48,-0.02)   
Day 5 141 1.15 ± 0.91 129 1.45 ± 1.15 -0.30  (-0.55,-0.05)   
Day 6 127 1.12 ± 0.82 112 1.42 ± 1.21 -0.30  (-0.57,-0.03)   
Day 7 111 1.13 ± 0.80 97 1.34 ± 1.12 -0.21  (-0.48,0.06)   
a
 Mean difference Vasopressin – Norepinephrine; figures may not add due to rounding 
b
 Number of subjects included in calculation of the mean 
 
  
b) 
 Hydrocortisone Placebo 
Difference
a 
(mg/dl) 
95% CI 
 N
b
 Mean ± SD 
(mg/dl) 
N
b
 Mean ± SD 
(mg/dl) 
Day 1 202 1.98 ± 1.71 204 1.72 ± 1.17 0.26  (-0.03,0.54)   
Day 2 186 1.74 ± 1.29 197 1.56 ± 1.10 0.18  (-0.07,0.41)   
Day 3 171 1.48 ± 1.02 179 1.42 ± 1.07 0.06  (-0.16,0.28)   
Day 4 148 1.35 ± 1.04 156 1.30 ± 1.01 0.05  (-0.19,0.27)   
Day 5 126 1.30 ± 1.11 144 1.29 ± 0.98 0.01  (-0.24,0.27)   
Day 6 113 1.24 ± 1.09 126 1.27 ± 0.98 -0.03  (-0.30,0.23)   
Day 7 99 1.18 ± 0.97 109 1.28 ± 0.96 -0.10  (-0.36,0.17)   
a
 Mean difference Hydrocortisone – Placebo; figures may not add due to rounding 
b
 Number of subjects included in calculation of the mean 
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eTable 7. Mean urine output over the first 7 days, a) vasopressin vs 
norepinephrine and b) hydrocortisone vs placebo.  
 
a) 
 Vasopressin Norepinephrine 
Difference
a 
(mls) 
95% CI  
N
b
 
Mean ± SD 
(mls) 
N
b
 
Mean ± SD 
(mls) 
Day 1
c 
205 737 ± 3813 204 1010 ± 2455 -273 (-454, -94) 
Day 2 189 1521 ± 2204 198 1628 ± 2182 -107 (-357, 142) 
Day 3 179 1833 ± 1811 182 1680 ± 1733 153 (-120, 427) 
Day 4 158 2199 ± 1620 157 1946 ± 1412 253 (-93, 598) 
Day 5 144 2451 ± 1736 133 2027 ± 1331 424 (32, 815) 
Day 6 129 2382 ± 1449 114 2062 ± 1316 320 (-106, 746) 
Day 7 114 2314 ± 1150 99 1906 ± 1363 408 (11, 804) 
a
 Mean difference Hydrocortisone – Placebo; figures may not add due to rounding 
b
 Number of subjects included in calculation of the mean 
c 
Day 1 runs from the time of randomization to the end of the “ICU calendar day” so it is therefore less than 24 hours 
and varies between patients. 
  
b) 
 Hydrocortisone Placebo 
Difference
a 
(mls) 
95% CI  
N
b
 
Mean ± SD 
(mls) 
N
b
 
Mean ± SD 
(mls) 
Day 1
c 
202 851 ± 4015 207 895 ± 2135 -44 (-226, 138) 
Day 2 189 1555 ± 2075 198 1595 ± 2306 -40 (-290, 210) 
Day 3 173 1753 ± 1970 188 1758 ± 1564 -5 (-279, 269) 
Day 4 153 2022 ± 1692 162 2120 ± 1337 -98 (-445, 249) 
Day 5 131 2318 ± 1791 146 2184 ± 1302 134 (-262, 530) 
Day 6 115 2314 ± 1588 128 2158 ± 1188 156 (-277, 589) 
Day 7 101 2131 ± 1349 112 2118 ± 1151 13 (-389, 414) 
a
 Mean difference Hydrocortisone – Placebo; figures may not add due to rounding 
b
 Number of subjects included in calculation of the mean 
c 
Day 1 runs from the time of randomization to the end of the “ICU calendar day” so it is therefore less than 24 hours 
and varies between patients. 
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eTable 10. Analysis of other organ failure–free days 
 Vasopressin Norepinephrine Vasopressin vs 
Norepinephrine, 
Absolute 
difference 
(95% CI) 
 
Hydrocortisone Placebo Total Hydrocortisone Placebo Total 
28-day survivors who never 
developed respiratory 
failure, N/Total (%)
a
 
29/66 
(43.9) 
27/63 
(42.9) 
56/129 
(43.4) 
26/60 
(43.3) 
37/63 
(58.7) 
63/123 
(51.2) 
-8.1 (-20.4,4.1) 
Respiratory failure free 
days in other patients
b
, 
days, median (IQR) 
10 (1,23) 18 (2,24) 16 (1,24) 18 (2,25) 18 (3,26) 18 (3,25) -2 (-9,5) 
28-day survivors who never 
developed liver failure, 
N/Total (%)
a
 
58/92 
(63.0) 
62/91 
(68.1) 
120/183 
(65.6) 
58/90 
(64.4) 
61/86 
(70.9) 
119/176 
(67.6) 
-2.0 (-11.8,7.7) 
Liver failure free days in 
other patients
b
, days, 
median (IQR) 
4 (1,10) 4 (1,16) 4 (1,14) 8 (1,21) 5 (2,20) 6 (2,21) -2 (-10,3) 
28-day survivors who never 
developed hematological 
failure, N/Total (%)
a
 
55/94 
(58.5) 
56/94 
(59.6) 
111/188 
(59.0) 
58/92 
(63.0) 
69/95 
(72.6) 
127/187 
(67.9) 
-8.1 (-18.9,0.5) 
 
Hematological failure free 
days in other patients
b
, 
days, median (IQR) 
6 (1,20) 12 (1,23) 8 (1,23) 7 (2,22) 6 (1,16) 6 (1,21) 2 (-8,7) 
Cardiovascular failure free 
days in all patients, median 
(IQR) 
22 (3,25) 22 (6,25) 22 (5,25) 24 (9,26) 25 (10,26) 24 (9,26) -2 (-4,0) 
a
 28 day survivors as a proportion of patients with no organ failure at baseline, excluding the following subjects with missing baseline organ failure data (7 for respiratory failure, 30 for liver failure, 11 
for hematological failure) 
b 
Other patients = those who died and / or had the corresponding acute organ failure at any time. 
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eTable 11. Outcome data comparing hydrocortisone groups with 
placebo groups 
 Hydrocortisone 
Total 
Placebo 
Total 
Hydrocortisone vs 
placebo, 
Absolute difference
a 
(95% CI) 
28-day survivors who never developed 
renal failure, N/Total (%)
b 
92/158 
(58.2) 
 
95/164 
(57.9) 
0.3 (-10.5, 11.1) 
Renal failure free days in other 
patients
c
, days, median (IQR) 
8 (0, 24) 14 (1, 25) -6 (-12, 4) 
28-day mortality, N/Total (%) 62/201 
(30.8) 
57/207 
(27.5) 
3.3 (-5.5, 12.1) 
ICU mortality, N/Total (%) 56/201 
(27.9) 
53/207 
(25.6) 
2.3 (-6.3, 10.9) 
Hospital mortality, N/Total (%) 66/201 
(32.8) 
62/207 
(30.0) 
2.9 (-6.1, 11.9) 
Renal Failure, N/Total (%) 87/202 
(43.1) 
97/202 
(46.9) 
-3.8 (-13.4,5.8) 
Duration of Renal Failure, days, 
median (IQR) 
4 (1,7) 3 (1,8) 1 (-1, 2) 
  Survivors 4 (2,7) 4 (2,8) 0 (-2, 3) 
  Non-survivors 3 (1,7) 2 (1,6) 1 (-1, 2) 
Use of renal replacement therapy, 
N/Total (%) 
61/202 
(30.2) 
63/207 
(30.4) 
-0.2 (-9.1, 8.7) 
Duration of renal replacement therapy, 
days median (IQR) 
3 (2,7) 3 (2,8) 0 (-2,2) 
  Survivors 4 (2,8) 4 (2,14) 0 (-4,4) 
  Non-survivors 3 (2,6) 3 (2,5) 0 (-2,2) 
Numbers weaned from vasopressors 
for >24hrs, N/Total (%) 
179/202 
(88.6) 
179/207 
(86.5) 
-2.1 (-4.3, 8.5) 
Time to shock reversal, hours median 
(IQR) 
48 (27,82) 48 (24,97) 0 (-15,10) 
Use of inotropes
d
, N/Total (%) 55/202 
(27.2) 
41/207 
(19.8) 
7.4 (-0.8, 15.6) 
Duration of mechanical ventilation, 
days median (IQR) 
5 (2,12) 6 (3,12) -1 (-3,1) 
Mean total SOFA score, Mean ± SD 6.1 (3.2) 6.1 (3.3) 0.0 (-0.6, 0.7) 
ICU length of stay, days median (IQR) 6 (3,11) 6 (3,12) 0 (-2,1) 
Hospital length of stay, days median 
(IQR) 
15 (7,34) 16 (8,39) -1 (-6,2) 
Patients who had one or more serious 
adverse events, N/Total (%) 
20/202 
(9.9) 
19/207 
(9.2) 
0.7 (-5.0, 6.4) 
Subcategories of serious adverse 
events e 
   
  Digital ischemia, N/Total (%) 6/202 
(3.0) 
8/207 
(3.9) 
-0.9 (-4.9,3.1) 
  Mesenteric ischemia, N/Total (%) 6/202 
(3.0) 
4/207 
(1.9) 
1.0 (-2.5,4.5) 
  Life threatening arrhythmia, N/Total 
(%) 
3/202 
(1.5) 
4/207 
(1.9) 
-0.4 (-3.4,2.5) 
  Acute Coronary Syndrome, N/Total 
(%)
 
6/202 
(3.0) 
3/207 
(1.4) 
1.5 (-1.8,4.9) 
  Other, N/Total (%) 5/202 
(2.5) 
3/207 
(1.4) 
1.0 (-2.2,4.2) 
SOFA – Sequential Organ Failure Assessment (range 0-20, a higher score corresponds to more severe organ 
failure)  
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a 
Absolute difference in percentage for binary variables and difference in medians for continuous variables.  95% 
confidence intervals for the difference in medians calculated using bootstrapping; figures may not add due to 
rounding. 
b
 28 day survivors as a proportion of patients with no organ failure at baseline 
c
 Other patients = those who died and / or had renal failure at any time.  
d 
inotropes defined as dobutamine, epinephrine, milrinone, dopamine, dopexamine.  
e 
The N of serious adverse events represents the number of patients who had that subcategory of event. Patients 
may have had more than one event. 
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